Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity

Hepatology

Volumn 43, Issue 3, 2006, Pages 581-591

  Levy, Gary A ^a,c   Adamson, Gord ^b   Phillips, M James ^a   Scrocchi, Louise A ^b   Fung, Laisum ^a   Biessels, Pieter ^b   Ng, Nancy F ^b   Ghanekar, Anand ^a   Rowe, Andrea ^a   Ma, Max Xuezhong ^a   Levy, Adam ^a   Koscik, Cheryl ^a   He, William ^d   Gorczynski, Reginald ^a   Brookes, Steve ^b   Woods, Caroline ^b   McGilvray, Ian D ^a   Bell, David ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Hemosol Inc   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; HEMOGLOBIN RIBAVIRIN CONJUGATE; INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; HEPATITIS; HEPATITIS C VIRUS; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LETHARGY; MACROMOLECULE; MACROPHAGE; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TISSUE NECROSIS; VIRUS HEPATITIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG DELIVERY SYSTEMS; FEMALE; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTES; LIVER FAILURE, ACUTE; MACROPHAGES; MICE; MICE, INBRED BALB C; MURINE HEPATITIS VIRUS; OUTCOME ASSESSMENT (HEALTH CARE); RIBAVIRIN; VIRUS REPLICATION;

EID: 33645232553     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21072     Document Type: Article

References (37)

1. National Institute of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. HEPATOLOGY 1997:26(Suppl):2S-10S.
2. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects of hepatitis C (in Japanese with English abstract). Jpn J Infect Dis Rev 2002:55:69-77.
3. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
4. Rosen HR, Martin P. Viral hepatitis in the liver transplant recipient. Infect Dis Clin North Am 2000;3:761-784.
5. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marines G, Concales FL Jr., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005:27:[Epub ahead of print]
6. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Castro 2004;39:668-673.
7. Fahmy TM, Samstein RM, Harness CC, Saltzman MW. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005;26:5727-5736.
8. Han J, Lim SJ, Lee MK, Kim CK. Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosyiated albumins. Drug Deliv 2001;8:125-134.
9. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman H-J, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
10. Kino K, Tsunoo H, Higa Y, Takami M, Nakajima H. Kinetic aspects of hemoglobin-haptoglobin receptor interaction in rat liver plasma membranes, isolated liver cells, and liver cells in primary culture. J Biol Chem 1982;257:4828-4833.
11. Oshiro S, Nakajima H. Intrahepatocellular site of the catabolism of heme and globin moiety of hemoglobin-haptoglobin after intravenous administration to rats. J Biol Chem 1988;263:16032-16038.
12. Hiraoka A, Horiike N, Akbar SMF, Michitaka K, Matsuyama T, Onji M. Expression of CD 163 in the liver of patients with viral hepatitis. Pathol Res Pract 2005;201:379-384.
13. Brookes S, Biessels P, Ng NFL, Woods C, Bell DN, Adamson G. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery. Bioconjug Chem 2006. In press.
14. Javid J. Human haptoglobins. Curr Top Hematol 1978;1:151-192.
15. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998;91:3841-3849.
16. Pope M, Rotstein O, Cole E, Sinclair S, Parr R, Cruz B, et al. Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication. J Virol 1995;69:252-5260.
17. Levy GA, Shaw R, Leibowitz JL, Cole E. The immune response to mouse hepatitis virus: genetic variation in antibody response and disease. Adv Exp Med Biol 1984;173:345-364.
18. Liu MF, Ning Q, Pope M, Mosmann T, Leibowitz J, Ding JW, et al. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. Adv Exp Med Biol 1998;440:415-423.
19. Allen LB, Boswell KH, Khwaja TA, Meyer RR, Sidwell RW, Witkowski JT. Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleosides 1-α-D-ribofuranosyl-1, 2, 4- triazole-3-carboxamide (Ribavirin). J Med Chem 1978;21:742-746.
20. Allen LB, Boswell KH, Khwaja TA, Meyer RR, Sidwell RW, Witkowski JT. Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleosides 1-α-D-ribofuranosyl-1, 2, 4- triazole-3-carboxamide (Ribavirin). J Med Chem 1978;21:742-746.
21. Fiume L, Busi G, di Stefano G, Mattioli A. Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters. Anal Biochem 1993;212:407-411.
22. Li C, Fung LS, Crow A, Myers-Mason N, Leibowitz JL, Cole E, et al. Monoclonal anti-prothrombinase (3D4.3) prevents mortality from murine hepatitis virus infection (MHV-3). J Exp Med 1992;176:689-697.
23. Mills DM, Zucker-Franklin D. Electron Microscopic Study of Isolated Kupffer cells. Am J Pathol 1969;154:147-166.
24. Sidwell RW, Huffman JH, Campbell N, Allen LB. Effect of ribavirin on viral hepatitis in laboratory animals. Ann N Y Acad Sci 1977;284:239-246.
25. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental human hepatitis. J Clin Invest 2003;112:58-66.
26. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine production response. J Immunol 1998;160:3487-3493.
27. Schaer DJ, Boretti FS, Hongegger A, Peohler D, Linnscheid P, Staege H, et al. Molecular cloning and characterization of the mouse CD 163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics 2001;53:179-177.
28. Sookoian S, Castano G, Flichman D, Cello J. Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production). Ann Hepatol 2004;3:104-107.
29. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during Interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004;39:668-673.
30. Jen J, Laughlin M, Cheng C. Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. Clin Pharm Ther 2002;72:349-361.
31. Levy GA, Leibowitz JL, Edgington TS. Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J Exp Med 1981;154:1150-1163.
32. Kino K, Tsunoo H, Higa Y, Takami M, Hamaguchi H, Nakajima H. Hemoglobin-haptoglobin receptor in rat liver plasma membrane. J Biol Chem 1980;255:9616-9620.
33. Okuda M, Tokunaga R, Taketani S. Expression of haptoglobin receptors in human hepatoma cells. Biochimica Biophys Acta 1992;1136:143-149.
34. Van Vlierbergh H, Delanghe JR, De Vos M, Lerous-Roel G. Factors influencing ribavirin-induced hemolysis, J Hepatol 2001;34:911-916.
35. Crespo J, Rivero M, Fabrega E, Cayon A, Amado JA, Garcia-Unzeta MT, et al. Plasma leptin and TNF-α levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;47:1604-1610.
36. Rockey D. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005;3:95-107.
37. Leifeld L, Ramakers J, Dumoulin F-L, Trautwein C, Sauerbruch T, Spengler U. Imbalanced intrahepatic expression of interleukin 12, Interferon gamma, and interleukin 10 in fulminant hepatitis B. HEPATOLOGY 2002;36:1001-1008.